5355 stories
·
16 followers

Dementia is rising, but your personal risk is falling | Vox

Vox
1 Comment and 2 Shares

I turned 48 this week, which meant it was time for my annual physical. After the usual battery of questions from my doctor — How much did I drink? Was I exercising? How was I sleeping? — it was my turn to ask a question. I had one prepared: Should I get the shingles vaccine?

  • Dementia cases will keep climbing as the population ages — a projected million new US cases annually by 2060 — but your odds of getting it at any given age have been falling for decades. An 80-year-old today is meaningfully less likely to have dementia than one a generation ago.
  • Across wealthy countries, age-specific dementia rates have dropped roughly 13 percent per decade since the late 1980s, and most of that decline tracks with things we can influence: better-controlled blood pressure and cholesterol, less smoking, more years of school. The brain lives downstream of the heart.
  • A 2024 Lancet commission estimated that up to 45 percent of dementia could be prevented or delayed by addressing 14 risk factors — and the highest-leverage window is midlife, not old age.
  • The anti-dementia to-do list: treat your blood pressure and LDL cholesterol, don’t smoke, stay physically active, get your hearing and vision checked, keep learning, and go easy on alcohol. Unglamorous, but it buys time for your brain.
  • A growing run of studies links the shingles vaccine to lower dementia risk. The evidence isn’t conclusive and the shot is only recommended at 50, but it’s worth a conversation with your doctor.
  • There is no drug that reverses dementia today. That’s not the same as being helpless.

According to standard medical guidance, the answer would be no. The shingles vaccine is only recommended by the government for people 50 years or older; the only exceptions are adults whose immune systems are weakened by disease or treatment. And despite the way my back feels when I get out of bed each morning, I wasn’t there quite yet. Our immune systems weaken as we age, but at 48, I was probably still capable of beating back the varicella-zoster virus that causes shingles (and chickenpox).

And yet my doctor was open to the idea for the same reason that I was asking about it: because there is early but growing evidence that the shingles vaccine may be protective against neurodegenerative diseases like dementia. For someone my age, with more time behind me than in front of me, the possibility of developing those diseases — and the desire to do anything to prevent them — is suddenly looming large.

I’m far from alone. Dementia already afflicts more than 6 million Americans today, and a 2025 study in Nature Medicine estimated that the lifetime risk of developing dementia after age 55 is 42 percent, with higher figures for women, Black adults, and those who carry the APOE ε4 allele genetic variant, which is known to increase the risk for Alzheimer’s. That same study projected new US cases of dementia would double by 2060, from 514,000 a year in 2020 to more than 1 million annually, due largely to population aging.

Behind those figures is a universe of suffering. Nearly everyone reading this has watched, or will watch, someone they love succumb to dementia. And once you get to my side of your 40s, that risk starts to feel less abstract and a lot more personal.

Yet the frightening story of the rise in dementia cases as the US population ages obscures real progress that is already being made to prevent it — and the even greater progress that could follow. Dementia may feel inevitable, a cruel side effect of longer life. But it doesn’t have to be.

The Nature study is about incidence — new cases, not the total number of people living with dementia. Separate CDC estimates project nearly 14 million older Americans living with Alzheimer’s disease, the most common form of dementia, by 2060.

But the rate hasn’t been holding steady — it’s been dropping. A 2020 study that drew on data from six countries across Europe and North America found that age-specific dementia incidence for people of European ancestry had fallen about 13 percent per decade since the late 1980s, and around 16 percent per decade for clinical Alzheimer’s. A 2016 study tracked five-year dementia rates across four periods between the late 1970s and the early 2000s and found them steadily falling, ultimately dropping 44 percent by the most recent period. The authors of the 2020 study project that if the decline in incidence remains steady in the future, 15 million fewer people might develop dementia by 2040 across high-income countries than if the incidence of the disease remained unchanged.

That good news may not be shared by everyone. The 2016 study found that the decline only showed up among people with at least a high school diploma — more on that below — and even then, it wasn’t evenly shared. And the sheer increase in older people means that a continually dropping incidence only blunts the coming dementia wave, rather than blocking it. One study of older adults in England actually found dementia incidence falling through 2008 and then creeping back up; the researchers also found that when you account for the fact that people headed toward dementia tend to die earlier, the drop gets much harder to see. What’s fallen before can rise again.

But what this likely means in practice is that a person turning 80 today is meaningfully less likely to have dementia than a person who turned 80 a generation ago. And it’s reasonable to hope the same will hold for whoever turns 80 next — like, say, me.

The question, though, is why.

Here’s a veteran health journalist tip: if anyone ever asks you why something is improving in public health, just attribute it to the decline in smoking. There’s a decent chance you’ll be right.

While Alzheimer’s is a brain disease, and dementia is the umbrella term for several kinds of cognitive decline, there is a growing consensus that they are deeply driven by vascular health — meaning what damages your heart and blood vessels is ultimately what damages your mind. Thanks to the development of blood pressure and cholesterol-lowering medicines, better heart disease and stroke management, and perhaps most of all, drastic reductions in smoking, cardiovascular health has been improving. Even with the rise of obesity and diabetes, most vascular risk factors have decreased over the same time that dementia and Alzheimer’s prevalence fell.

The rise in education over the same time period may play a role as well. Americans turning 80 today went to school during a great mid-century expansion in education, while their parents were schooled — or rather, not schooled — in the 1920s and ’30s. In 1940, only 24.5 percent of Americans 25 and older had a high school diploma, and just 4.6 percent had completed a bachelor’s degree or more. By 2017, high school completion had reached 90 percent, and the share of people with a bachelor’s or more had hit 34 percent. And researchers have correlated higher education attainment with lower dementia and Alzheimer’s rates.

Now repeat after me: correlation is not causation. Researchers don’t really know why more years of schooling seem to be associated with a lower risk of dementia, though there are theories that education might boost the brain’s “cognitive reserve.” But the hopeful take is that the decline in incidence is largely driven by behaviors and life conditions we can change. And one of the most unexpected and promising acts is something as simple as routine vaccination.

Last April, I wrote about what I called “one of the brightest spots in an otherwise dark field”: a study in Wales that found that older adults who received a vaccine against shingles were 20 percent less likely to develop dementia in the seven years following vaccination than those who did not receive it. It wasn’t a randomized trial, but it was stronger than the usual observational association: the study harnessed a natural experiment in Wales, where vaccine eligibility turned on a birthday cutoff, meaning it was less likely that the results were because vaccinated people were simply healthier.

Earlier this year, a study in Canada looked at hundreds of thousands of people over the age of 70 and, like the Welsh study, found that those who had taken the shingles vaccine were less likely to develop dementia. And a new analysis from late 2025 of the data in the Welsh study found that the vaccine was associated with benefits that went beyond prevention — it also seemed to slow the disease for those with dementia and reduced deaths attributable to it.

The shingles vaccine in the Welsh study was an older, live-virus version; the current vaccine is a newer recombinant form that can’t accidentally cause shingles, and another study found it was associated with even greater protection from dementia.

These findings are promising but still leave plenty of questions. The Welsh live-vaccine study found a larger apparent benefit in women, who also suffer higher rates of dementia. But the pattern is not settled: the newer recombinant-vaccine study found an association in both men and women, though stronger in women. Shingles may be connected to dementia, though the evidence is still messy: A large 2025 health-records study found recurrent shingles was associated with a modestly higher dementia risk than a single episode, while earlier evidence has been more mixed.

Shingles occurs when the dormant varicella zoster virus — the same virus that causes chickenpox — reactivates. It’s possible that the resulting neural inflammation may feed dementia. A randomized controlled trial published in December tested a related herpes-virus idea, treating 120 adults with early Alzheimer’s or mild cognitive impairment — all with evidence of prior herpes simplex infection — with a medication called valacyclovir. After 18 months, researchers found no significant advantage over a placebo, dampening hopes that herpes antivirals could be an effective Alzheimer’s treatment.

That’s a real strike against the simplest version of the theory that the virus itself is rotting the brain. But it could mean that the shingles vaccine’s possible protective effects don’t come from shingles at all. A 2025 study found that the newer shingles vaccine and an RSV vaccine that share the same AS01 immune-boosting adjuvant were each associated with lower 18-month dementia risk compared with flu vaccination, and researchers did not find a statistically significant difference between the two AS01 vaccines. The implication is that the benefit might come from giving an aging immune system a jolt, rather than from any one bug it’s aimed at.

But as the vaccine science sorts itself out, there are lifestyle changes you can make to help protect yourself without getting a shot. A 2024 Lancet commission found that, in principle, up to 45 percent of dementia cases could be prevented or delayed by addressing 14 risk factors, including not smoking; lowering high LDL cholesterol in midlife; treating hearing loss, especially from midlife on; and limiting obesity. The key period here is midlife, which the commission defined (rather widely in my opinion) as 18-65. Which, for someone my age, means there’s no better time to focus on prevention.

I don’t know whether I’ll go ahead and try to get the shingles vaccine early, and to be clear, I’m not telling anyone they should. The science is still uncertain, and I am, obviously, not a medical doctor. But the lifestyle factors that have been shown to protect against dementia — which are largely the same ones that help cardiovascular health — can be adopted by everyone, for their health now and in the future.

No one knows for sure what the future holds, for me or for you. What’s certain is that, barring a medical miracle, the sheer number of dementia cases will continue to rise as our population ages, and that some of us will be in that number. But that doesn’t mean we’re helpless.

A version of this story originally appeared in the Good News newsletter. Sign up here!

You’ve read 1 article in the last month

Here at Vox, we're unwavering in our commitment to covering the issues that matter most to you — threats to democracy, immigration, reproductive rights, the environment, and the rising polarization across this country.

Our mission is to provide clear, accessible journalism that empowers you to stay informed and engaged in shaping our world. By becoming a Vox Member, you directly strengthen our ability to deliver in-depth, independent reporting that drives meaningful change.

We rely on readers like you — join us.

Swati Sharma

Swati Sharma

Vox Editor-in-Chief

Read the whole story
acdha
21 hours ago
reply
Close to home age-wise 💉
Washington, DC
mareino
4 hours ago
reply
Washington, District of Columbia
Share this story
Delete

A slavery exhibit becomes a flashpoint in Philadelphia ahead of America's 250th

2 Shares

Activists in Philadelphia are fighting to restore an exhibit about enslaved people who lived and worked in George Washington's presidential household.

Read the whole story
mareino
4 hours ago
reply
Washington, District of Columbia
acdha
1 day ago
reply
Washington, DC
Share this story
Delete

Photo

1 Share


Read the whole story
mareino
2 days ago
reply
Washington, District of Columbia
Share this story
Delete

Researchers are uncovering ADHD’s links to these other health conditions

1 Share

Attention-deficit/hyperactivity disorder, or ADHD, is one of the most common neurodevelopmental conditions in the United States, affecting an estimated 15.5 million adults and roughly 7 million children.

A growing body of evidence suggests that people with ADHD may be at risk for other health conditions, including anxiety, disordered eating, autoimmune disease, migraines, long covid and chronic pelvic pain.

For example, in a study published this spring in Scientific Reports, researchers looked at 958 adults with treatment-resistant chronic pain. They found that those with “extremely severe” pain — consistently rated 9 or 10 on a 10-point scale — were more likely to have ADHD symptoms than those with less severe pain. Overall, ADHD symptoms were about twice as common in the study group as in the general population.

What’s not clear, however, is whether there is a direct biological link between ADHD and pain (or any other condition), or whether years of stress, overwhelm, poor sleep patterns, social difficulties, untreated ADHD symptoms and side effects of ADHD medications are the real culprits.

We spoke with experts and dug into the research to understand more about the complex connections.

ADHD and pain

As the new study and other research suggest, adults with ADHD are more likely to report chronic pain and may experience greater pain severity in conditions such as migraine, fibromyalgia and chronic low-back pain.

Karen Stewart, a clinical psychologist based in Huntsville, Alabama, who specializes in ADHD, said impulsivity and cognitive rigidity (difficulty adapting to new thoughts or behaviors), both of which are common ADHD traits, may help explain this connection.

“Our beliefs about our pain and our reactions can amplify or ameliorate our physical suffering,” Stewart said. For example, catastrophizing or quickly jumping to worst-case scenarios, which can be an aspect of impulsivity, and not being able to shake those thoughts, which can be part of cognitive rigidity, can ultimately increase your perception of pain, she said.

People with ADHD who are experiencing pain, in particular, can sometimes become consumed by fears that their symptoms will never improve, said Margo Pumar, a psychiatrist who specializes in ADHD and reproductive psychiatry in San Francisco. This can lead to a looping internal dialogue along the lines of: “I can’t have this keep happening. I can’t live this way. What if I always have to live this way?”

Imagining the worst-case scenario may also amplify nerve sensitivity, a phenomenon called central sensitization, which research suggests is more common in people with ADHD. This describes when your nervous system becomes hypersensitive to sensory signals, which can magnify your perception of discomfort and pain.

Neuroinflammation — which is when the tissues in the brain or spinal cord become inflamed and is one of the factors that play a role in ADHD — may additionally increase your risk of experiencing central sensitization. (ADHD is generally thought to be caused by a complex mix of genetic and environmental factors.)

Eugene Merzon, an ADHD researcher and Israeli Health Ministry-certified ADHD diagnostician, explained that neuroinflammation may disrupt how neurons in the brain communicate and function, resulting in ADHD’s signature symptoms, such as inattention and executive dysfunction.

What causes neuroinflammation is unclear, but in addition to potentially influencing brain development and increasing the risk of disorders such as ADHD, research has suggested that “ongoing inflammation may overstimulate the nervous system, making symptoms like pain, fatigue and memory problems worse over time,” said Valentin Dragoi, a professor of neuroscience at Houston Methodist Academic Institute.

ADHD is linked to chronic pain and other health conditions. (iStock)

ADHD and the immune system

ADHD also seems to co-occur with disorders of immune function, such as asthma, allergies, eczema, rheumatoid arthritis, Type 1 diabetes and hypothyroidism, said Jeffrey Newcorn, director of the division of ADHD and learning disorders within the department of psychiatry at Mount Sinai in New York.

In one of Merzon’s studies, he and his team of researchers found that having a diagnosis of ADHD was associated with a higher risk of covid infection early in the pandemic, more severe illness and a greater likelihood of long covid, raising questions about how neuroinflammation affects the immune system.

Another study that he co-authored found that children diagnosed with ADHD had elevated inflammatory markers, including higher eosinophil (immune cells involved in allergic and inflammatory responses) counts, as early 1 year old.

Brain scans reveal 3 ADHD subtypes, including a more extreme form

ADHD drugs work, but not the way experts thought

Researchers have also explored these connections in autoimmune conditions such as lupus. Neuropsychiatric lupus, an umbrella term describing the neurological and psychiatric symptoms that can occur in people with systemic lupus erythematosus (SLE), can lead to symptoms that mirror ADHD-related brain fog.

For years, many lupus patients were told these symptoms — such as difficulty concentrating, short-term memory loss, mixing up words and difficulty completing thoughts — were simply emotional reactions to chronic illness, said Meggan Mackay, a Lupus Research Alliance-funded researcher, rheumatologist and professor at the Feinstein Institutes for Medical Research. But growing evidence suggests neuroinflammation could be at the root of these symptoms.

Navigating ADHD and other conditions

People with ADHD may also have a more difficult time navigating complex health conditions, Newcorn said, which could result in worse symptoms or more severe outcomes.

That’s because managing chronic illness — remembering medications, monitoring symptoms, attending appointments and maintaining consistent sleep schedules — requires high levels of executive function, or the collection of mental skills that help people plan, prioritize, manage time and follow through on tasks. Executive dysfunction is a classic manifestation of ADHD.

Research suggests that stimulant medications used to treat ADHD and multiple types of antidepressants also could help improve chronic pain and mood disorders that can occur alongside ADHD.

Ultimately, the science surrounding ADHD and chronic illness is still evolving. “The human brain is infinitely complex and difficult to understand and study,” Dragoi said. But the thing that experts did stress is that we need to stop looking at ADHD as just a condition that affects the brain.

“It’s one body,” Pumar said. “There are no secrets. Your brain knows exactly what’s happening in all the parts of your body.”

Read the whole story
mareino
2 days ago
reply
Washington, District of Columbia
Share this story
Delete

“In times of great uncertainty, people-at-large will act cautiously and avoid committing themselves…

1 Share

“In times of great uncertainty, people-at-large will act cautiously and avoid committing themselves to major resource outlays, or else make desperate flailing gambles when they feel really backed into a corner. This isn’t because anyone is being evil or stupid. It’s necessary, predictable, and wise on a micro-level.”

“The nature of technological development is such that, for the foreseeable future, literally all times will be times of great uncertainty.”

Someone oughta, y'know, look into that.

Read the whole story
mareino
3 days ago
reply
Washington, District of Columbia
Share this story
Delete

The Amazing Digital Circus Beats Estimates With $36.6M Global Haul

1 Comment
Box Office ReportSeriesStreaming

Weekend actuals are in, and once again, The Amazing Digital Circus has surpassed all expectations and beaten estimates, pulling in a $36.6 Million global haul over four days.

The Last Act, the highly anticipated finale of Gooseworx and Glitch Productions’ landmark YouTube-native indie animated series, was initially projected to finish the four-day window, Thursday-Sunday, at around $35 million. Actual results released Tuesday by distributors Glitch, Fathom Entertainment, and Piece of Magic Entertainment pushed the total more than a million dollars higher, making the theatrical finale one of the biggest box office successes ever achieved by a digital-native animation property.

In North America, the film earned more than $20.2 million during its four-day opening frame in over 2,200 theaters. Fathom Entertainment said the release set company records for presales, three-day grosses, and four-day grosses. The film ranked third among new releases and fifth overall for the weekend.

Europe contributed another $12.7 million from approximately 3,000 screens across 38 markets. According to distributor Piece of Magic Entertainment, the film ranked first on opening day in the U.K., France, Benelux, Spain, and Poland, and finished among the weekend’s five highest-grossing titles in most European territories.

Mexico added $2.1 million and roughly 585,000 admissions, while Australia and New Zealand generated nearly $1.6 million combined.

Caspar Nadaud, CEO & Founder of the special’s European distributor Piece of Magic Entertainment, said in a release:

This result showcases that cinemas have a unique power to bring fan communities together. It is also a testament that such releases can scale across territories and deliver outstanding box office results. We are proud to have partnered with Glitch Productions and to have been part of turning a digital-first franchise into a true international big-screen event.

Ray Nutt, CEO of the North American distributor Fathom Entertainment, added:

The Amazing Digital Circus: The Last Act established several Fathom Entertainment presales records and scored a jaw-dropping $20M+ in box office receipts over the first four days in theatres, illustrating the power and appeal of bringing innovative content with established fanbases to the big screen.

The Amazing Digital Circus first launched on YouTube in 2023 and has since accumulated more than one billion views online. The theatrical release combines episodes eight and nine of the series and serves as the franchise’s concluding chapter, and a milestone moment in independent animation history.

What Do You Think?

Read the whole story
mareino
7 days ago
reply
The #5 movie in American theaters was a YouTube cartoon about mental illness and existentialism. And it was glorious.
Washington, District of Columbia
Share this story
Delete
Next Page of Stories